Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoylenurea SCHEMBL29460047 | 0.77 | KDM4E (0.45) | LMNAHTTGPR3TSHRKMT2A | |
| Benzoylenurea SCHEMBL1752723 | 0.77 | KDM4E (0.45) | LMNAHTTGPR3TSHRKMT2A | |
| SCHEMBL196601 | 0.77 | GPR3 (0.64) | LMNAHTTGPR3PRNPTSHR | |
| SCHEMBL266459 | 0.77 | CYP1A2 (0.64) | HTTGPR3MEN1KMT2ACYP1A2 | |
| SCHEMBL30199873 | 0.77 | CYP1A2 (0.64) | HTTGPR3MEN1KMT2ACYP1A2 | |
| SCHEMBL29461212 | 0.76 | TDP1 (0.54) | LMNAHTTGPR3PRNPTSHR | |
| Ammonia Solution, Strong SCHEMBL2184448 | 0.76 | GPR3 (0.61) | LMNAHTTGPR3PRNPTSHR | |
| SCHEMBL856788 | 0.76 | TDP1 (0.54) | LMNAHTTGPR3PRNPTSHR | |
| SCHEMBL8284883 | 0.75 | LMNA (0.47) | LMNATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL29892219 | 0.75 | CYP1A2 (0.41) | LMNACYP1A2ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118090990-A | Preparation method of stable isotope labeled hypnone internal standard reagent | 谱同生物医药科技(常州)有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED | 2002-04-04 | — | — | US | claimed |
| US-6251913-B1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED (GB) | 2001-06-26 | — | — | US | claimed |
| EP-0971895-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | claimed |
| WO-1998043959-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | claimed |
| US-20260115285-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4582101-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250127907-A1 | PARP INHIBITORS | Stablix, Inc. | 2025-04-24 | — | — | US | disclosed |
| WO-2024264072-A2 | PARP INHIBITORS | Stablix, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240239805-A1 | AZA-YANG CYCLIZATION-BUCHNER AROMATIC RING EXPANSION: COLLECTIVE SYNTHESIS OF CYCLOHEPTATRIENE-CONTAINING AZETIDINE LACTONES | UNIVERSITY OF KANSAS | 2024-07-18 | — | — | US | disclosed |
| CN-1050604-C | Compound with antipsychotic effect | MEIJI SEIKA KABUSHIKA KAISHA (JP) | 2000-03-22 | — | — | CN | disclosed |
| EP-0971895-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998043959-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
| US-5599815-A | SIDE EFFECT REDUCTION | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-02-04 | — | — | US | disclosed |
| CN-1103534-A | Compound with antipsychotic effect | MEIJI SEIKA CO (JP) | 1995-06-07 | — | — | CN | disclosed |
| EP-0635506-A1 | COMPOUND WITH ANTIPSYCHOTIC EFFECT | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239805-A1 | AZA-YANG CYCLIZATION-BUCHNER AROMATIC RING EXPANSION: COLLECTIVE SYNTHESIS OF CYCLOHEPTATRIENE-CONTAINING AZETIDINE LACTONES | AZI2, NISCH, TET2 | LMNA 4831/4885HTT 1123/4885GPR3 3332/4885 |
| US-20260115285-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | PARP11, PARP1, PARP14 | LMNA 840/4885HTT 4580/4885GPR3 4102/4885 |
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | MMP1, HCAR1, MMP13 | LMNA 1557/4885HTT 2229/4885GPR3 1731/4885 |
| US-20250127907-A1 | PARP INHIBITORS | PARP1, PARP2, PARP3 | LMNA 462/4885HTT 1568/4885GPR3 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.